[Second malignancies following Hodgkin's disease treatment in Tunisia. Retrospective study of 26 cases observed at the institute Salah-Azaïz].
Identifieur interne : 000069 ( PubMed/Checkpoint ); précédent : 000068; suivant : 000070[Second malignancies following Hodgkin's disease treatment in Tunisia. Retrospective study of 26 cases observed at the institute Salah-Azaïz].
Auteurs : L. Kochbati [Tunisie] ; H. Boussen ; F. Benna ; Z. Belhaj Ali ; A. Gammoudi ; N. Bouaouina ; M. Besbes ; L. Ghilen ; K. Rahal ; M. MaalejSource :
- Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique [ 1278-3218 ] ; 2003.
Descripteurs français
- KwdFr :
- Adolescent, Adulte, Adulte d'âge moyen, Bléomycine (administration et posologie), Chlorméthine (effets indésirables), Dacarbazine (administration et posologie), Doxorubicine (administration et posologie), Enfant, Facteurs de risque, Femelle, Humains, Incidence, Maladie de Hodgkin (radiothérapie), Maladie de Hodgkin (traitement médicamenteux), Mâle, Prednisone (effets indésirables), Procarbazine (effets indésirables), Protocoles de polychimiothérapie antinéoplasique (administration et posologie), Protocoles de polychimiothérapie antinéoplasique (effets indésirables), Protocoles de polychimiothérapie antinéoplasique (usage thérapeutique), Seconde tumeur primitive (épidémiologie), Seconde tumeur primitive (étiologie), Tunisie (épidémiologie), Vinblastine (administration et posologie), Vincristine (effets indésirables), Études rétrospectives.
- MESH :
- administration et posologie : Bléomycine, Dacarbazine, Doxorubicine, Protocoles de polychimiothérapie antinéoplasique, Vinblastine.
- effets indésirables : Chlorméthine, Prednisone, Procarbazine, Protocoles de polychimiothérapie antinéoplasique, Vincristine.
- radiothérapie : Maladie de Hodgkin.
- traitement médicamenteux : Maladie de Hodgkin.
- usage thérapeutique : Protocoles de polychimiothérapie antinéoplasique.
- épidémiologie : Seconde tumeur primitive, Tunisie.
- étiologie : Seconde tumeur primitive.
- Adolescent, Adulte, Adulte d'âge moyen, Enfant, Facteurs de risque, Femelle, Humains, Incidence, Mâle, Études rétrospectives.
- Wicri :
- geographic : Tunisie.
English descriptors
- KwdEn :
- Adolescent, Adult, Antineoplastic Combined Chemotherapy Protocols (administration & dosage), Antineoplastic Combined Chemotherapy Protocols (adverse effects), Antineoplastic Combined Chemotherapy Protocols (therapeutic use), Bleomycin (administration & dosage), Child, Dacarbazine (administration & dosage), Doxorubicin (administration & dosage), Female, Hodgkin Disease (drug therapy), Hodgkin Disease (radiotherapy), Humans, Incidence, Male, Mechlorethamine (adverse effects), Middle Aged, Neoplasms, Second Primary (epidemiology), Neoplasms, Second Primary (etiology), Prednisone (adverse effects), Procarbazine (adverse effects), Retrospective Studies, Risk Factors, Tunisia (epidemiology), Vinblastine (administration & dosage), Vincristine (adverse effects).
- MESH :
- chemical , administration & dosage : Bleomycin, Dacarbazine, Doxorubicin, Vinblastine.
- chemical , adverse effects : Vincristine.
- geographic , epidemiology : Tunisia.
- administration & dosage : Antineoplastic Combined Chemotherapy Protocols.
- adverse effects : Antineoplastic Combined Chemotherapy Protocols, Mechlorethamine, Prednisone, Procarbazine.
- drug therapy : Hodgkin Disease.
- epidemiology : Neoplasms, Second Primary.
- etiology : Neoplasms, Second Primary.
- radiotherapy : Hodgkin Disease.
- therapeutic use : Antineoplastic Combined Chemotherapy Protocols.
- Adolescent, Adult, Child, Female, Humans, Incidence, Male, Middle Aged, Retrospective Studies, Risk Factors.
Abstract
To collect second cancers in patients treated for Hodgkin disease (HD) during adolescence and young adulthood at Salah Azaïz Institute of Tunis.
PubMed: 14522350
Affiliations:
Links toward previous steps (curation, corpus...)
Links to Exploration step
pubmed:14522350Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">[Second malignancies following Hodgkin's disease treatment in Tunisia. Retrospective study of 26 cases observed at the institute Salah-Azaïz].</title><author><name sortKey="Kochbati, L" sort="Kochbati, L" uniqKey="Kochbati L" first="L" last="Kochbati">L. Kochbati</name><affiliation wicri:level="1"><nlm:affiliation>Service de radiothérapie carcinologie, institut Salah-Azaïz, boulevard Bab-Saadoun 1006 Tunis, Tunisie. lofti.kochbati@rns.tn</nlm:affiliation><country xml:lang="fr">Tunisie</country><wicri:regionArea>Service de radiothérapie carcinologie, institut Salah-Azaïz, boulevard Bab-Saadoun 1006 Tunis</wicri:regionArea><wicri:noRegion>boulevard Bab-Saadoun 1006 Tunis</wicri:noRegion></affiliation></author><author><name sortKey="Boussen, H" sort="Boussen, H" uniqKey="Boussen H" first="H" last="Boussen">H. Boussen</name></author><author><name sortKey="Benna, F" sort="Benna, F" uniqKey="Benna F" first="F" last="Benna">F. Benna</name></author><author><name sortKey="Belhaj Ali, Z" sort="Belhaj Ali, Z" uniqKey="Belhaj Ali Z" first="Z" last="Belhaj Ali">Z. Belhaj Ali</name></author><author><name sortKey="Gammoudi, A" sort="Gammoudi, A" uniqKey="Gammoudi A" first="A" last="Gammoudi">A. Gammoudi</name></author><author><name sortKey="Bouaouina, N" sort="Bouaouina, N" uniqKey="Bouaouina N" first="N" last="Bouaouina">N. Bouaouina</name></author><author><name sortKey="Besbes, M" sort="Besbes, M" uniqKey="Besbes M" first="M" last="Besbes">M. Besbes</name></author><author><name sortKey="Ghilen, L" sort="Ghilen, L" uniqKey="Ghilen L" first="L" last="Ghilen">L. Ghilen</name></author><author><name sortKey="Rahal, K" sort="Rahal, K" uniqKey="Rahal K" first="K" last="Rahal">K. Rahal</name></author><author><name sortKey="Maalej, M" sort="Maalej, M" uniqKey="Maalej M" first="M" last="Maalej">M. Maalej</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2003">2003</date><idno type="RBID">pubmed:14522350</idno><idno type="pmid">14522350</idno><idno type="wicri:Area/PubMed/Corpus">000072</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000072</idno><idno type="wicri:Area/PubMed/Curation">000072</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000072</idno><idno type="wicri:Area/PubMed/Checkpoint">000072</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000072</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">[Second malignancies following Hodgkin's disease treatment in Tunisia. Retrospective study of 26 cases observed at the institute Salah-Azaïz].</title><author><name sortKey="Kochbati, L" sort="Kochbati, L" uniqKey="Kochbati L" first="L" last="Kochbati">L. Kochbati</name><affiliation wicri:level="1"><nlm:affiliation>Service de radiothérapie carcinologie, institut Salah-Azaïz, boulevard Bab-Saadoun 1006 Tunis, Tunisie. lofti.kochbati@rns.tn</nlm:affiliation><country xml:lang="fr">Tunisie</country><wicri:regionArea>Service de radiothérapie carcinologie, institut Salah-Azaïz, boulevard Bab-Saadoun 1006 Tunis</wicri:regionArea><wicri:noRegion>boulevard Bab-Saadoun 1006 Tunis</wicri:noRegion></affiliation></author><author><name sortKey="Boussen, H" sort="Boussen, H" uniqKey="Boussen H" first="H" last="Boussen">H. Boussen</name></author><author><name sortKey="Benna, F" sort="Benna, F" uniqKey="Benna F" first="F" last="Benna">F. Benna</name></author><author><name sortKey="Belhaj Ali, Z" sort="Belhaj Ali, Z" uniqKey="Belhaj Ali Z" first="Z" last="Belhaj Ali">Z. Belhaj Ali</name></author><author><name sortKey="Gammoudi, A" sort="Gammoudi, A" uniqKey="Gammoudi A" first="A" last="Gammoudi">A. Gammoudi</name></author><author><name sortKey="Bouaouina, N" sort="Bouaouina, N" uniqKey="Bouaouina N" first="N" last="Bouaouina">N. Bouaouina</name></author><author><name sortKey="Besbes, M" sort="Besbes, M" uniqKey="Besbes M" first="M" last="Besbes">M. Besbes</name></author><author><name sortKey="Ghilen, L" sort="Ghilen, L" uniqKey="Ghilen L" first="L" last="Ghilen">L. Ghilen</name></author><author><name sortKey="Rahal, K" sort="Rahal, K" uniqKey="Rahal K" first="K" last="Rahal">K. Rahal</name></author><author><name sortKey="Maalej, M" sort="Maalej, M" uniqKey="Maalej M" first="M" last="Maalej">M. Maalej</name></author></analytic><series><title level="j">Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique</title><idno type="ISSN">1278-3218</idno><imprint><date when="2003" type="published">2003</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adolescent</term><term>Adult</term><term>Antineoplastic Combined Chemotherapy Protocols (administration & dosage)</term><term>Antineoplastic Combined Chemotherapy Protocols (adverse effects)</term><term>Antineoplastic Combined Chemotherapy Protocols (therapeutic use)</term><term>Bleomycin (administration & dosage)</term><term>Child</term><term>Dacarbazine (administration & dosage)</term><term>Doxorubicin (administration & dosage)</term><term>Female</term><term>Hodgkin Disease (drug therapy)</term><term>Hodgkin Disease (radiotherapy)</term><term>Humans</term><term>Incidence</term><term>Male</term><term>Mechlorethamine (adverse effects)</term><term>Middle Aged</term><term>Neoplasms, Second Primary (epidemiology)</term><term>Neoplasms, Second Primary (etiology)</term><term>Prednisone (adverse effects)</term><term>Procarbazine (adverse effects)</term><term>Retrospective Studies</term><term>Risk Factors</term><term>Tunisia (epidemiology)</term><term>Vinblastine (administration & dosage)</term><term>Vincristine (adverse effects)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Adolescent</term><term>Adulte</term><term>Adulte d'âge moyen</term><term>Bléomycine (administration et posologie)</term><term>Chlorméthine (effets indésirables)</term><term>Dacarbazine (administration et posologie)</term><term>Doxorubicine (administration et posologie)</term><term>Enfant</term><term>Facteurs de risque</term><term>Femelle</term><term>Humains</term><term>Incidence</term><term>Maladie de Hodgkin (radiothérapie)</term><term>Maladie de Hodgkin (traitement médicamenteux)</term><term>Mâle</term><term>Prednisone (effets indésirables)</term><term>Procarbazine (effets indésirables)</term><term>Protocoles de polychimiothérapie antinéoplasique (administration et posologie)</term><term>Protocoles de polychimiothérapie antinéoplasique (effets indésirables)</term><term>Protocoles de polychimiothérapie antinéoplasique (usage thérapeutique)</term><term>Seconde tumeur primitive (épidémiologie)</term><term>Seconde tumeur primitive (étiologie)</term><term>Tunisie (épidémiologie)</term><term>Vinblastine (administration et posologie)</term><term>Vincristine (effets indésirables)</term><term>Études rétrospectives</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Bleomycin</term><term>Dacarbazine</term><term>Doxorubicin</term><term>Vinblastine</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Vincristine</term></keywords><keywords scheme="MESH" type="geographic" qualifier="epidemiology" xml:lang="en"><term>Tunisia</term></keywords><keywords scheme="MESH" qualifier="administration & dosage" xml:lang="en"><term>Antineoplastic Combined Chemotherapy Protocols</term></keywords><keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>Bléomycine</term><term>Dacarbazine</term><term>Doxorubicine</term><term>Protocoles de polychimiothérapie antinéoplasique</term><term>Vinblastine</term></keywords><keywords scheme="MESH" qualifier="adverse effects" xml:lang="en"><term>Antineoplastic Combined Chemotherapy Protocols</term><term>Mechlorethamine</term><term>Prednisone</term><term>Procarbazine</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Hodgkin Disease</term></keywords><keywords scheme="MESH" qualifier="effets indésirables" xml:lang="fr"><term>Chlorméthine</term><term>Prednisone</term><term>Procarbazine</term><term>Protocoles de polychimiothérapie antinéoplasique</term><term>Vincristine</term></keywords><keywords scheme="MESH" qualifier="epidemiology" xml:lang="en"><term>Neoplasms, Second Primary</term></keywords><keywords scheme="MESH" qualifier="etiology" xml:lang="en"><term>Neoplasms, Second Primary</term></keywords><keywords scheme="MESH" qualifier="radiotherapy" xml:lang="en"><term>Hodgkin Disease</term></keywords><keywords scheme="MESH" qualifier="radiothérapie" xml:lang="fr"><term>Maladie de Hodgkin</term></keywords><keywords scheme="MESH" qualifier="therapeutic use" xml:lang="en"><term>Antineoplastic Combined Chemotherapy Protocols</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Maladie de Hodgkin</term></keywords><keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Protocoles de polychimiothérapie antinéoplasique</term></keywords><keywords scheme="MESH" qualifier="épidémiologie" xml:lang="fr"><term>Seconde tumeur primitive</term><term>Tunisie</term></keywords><keywords scheme="MESH" qualifier="étiologie" xml:lang="fr"><term>Seconde tumeur primitive</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adolescent</term><term>Adult</term><term>Child</term><term>Female</term><term>Humans</term><term>Incidence</term><term>Male</term><term>Middle Aged</term><term>Retrospective Studies</term><term>Risk Factors</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Adolescent</term><term>Adulte</term><term>Adulte d'âge moyen</term><term>Enfant</term><term>Facteurs de risque</term><term>Femelle</term><term>Humains</term><term>Incidence</term><term>Mâle</term><term>Études rétrospectives</term></keywords><keywords scheme="Wicri" type="geographic" xml:lang="fr"><term>Tunisie</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">To collect second cancers in patients treated for Hodgkin disease (HD) during adolescence and young adulthood at Salah Azaïz Institute of Tunis.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">14522350</PMID><DateCreated><Year>2003</Year><Month>10</Month><Day>2</Day></DateCreated><DateCompleted><Year>2003</Year><Month>11</Month><Day>12</Day></DateCompleted><DateRevised><Year>2015</Year><Month>11</Month><Day>19</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1278-3218</ISSN><JournalIssue CitedMedium="Print"><Volume>7</Volume><Issue>5</Issue><PubDate><Year>2003</Year><Month>Oct</Month></PubDate></JournalIssue><Title>Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique</Title><ISOAbbreviation>Cancer Radiother</ISOAbbreviation></Journal><ArticleTitle>[Second malignancies following Hodgkin's disease treatment in Tunisia. Retrospective study of 26 cases observed at the institute Salah-Azaïz].</ArticleTitle><Pagination><MedlinePgn>302-7</MedlinePgn></Pagination><Abstract><AbstractText Label="PURPOSE" NlmCategory="OBJECTIVE">To collect second cancers in patients treated for Hodgkin disease (HD) during adolescence and young adulthood at Salah Azaïz Institute of Tunis.</AbstractText><AbstractText Label="METHODS AND PATIENTS" NlmCategory="METHODS">We consider as second cancer all tumours other than HD observed in patients after treatment for HD.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Twenty-five patients among 614 treated for HD between 1975 and 1991 developed 26 secondary tumours (4.2%). There were 17 males and eight females (sex ratio 2:1). Mean age at the diagnosis of HD was 32.5 years (12-56). HD was stage II (eight cases), stage III (14) and stage IV in three. The first treatment was combined chemotherapy and radiotherapy in 22 cases and only chemotherapy in three cases (stage IV). Radiotherapy was delivered with Cobalt 60 by large fields. Mean dose was 41.3 Gy (2 Gy/fraction in 21 and 3.3 in one). Chemotherapy was MOPP (13), MOPP and vinblastine (four), MOPP-ABVD (five), ABVD (two) and vinblastine only in one. Mean delay of second tumours was 114.5 months (40-276). There was five acute myeloid leukaemia, two digestive non-Hodgkin lymphomas, five nodal high-grade lymphomas, three breast cancers (one in man associated with thyroid cancer), five lung cancers (three non-small cell and two of small cell type), two gastric tumours and one rectal cancer, one synovialosarcoma of the knee and one malignant Schwannoma of the neck. Median survival was 12.5 months (2-48). Twenty-one patients died and four are still alive with 8, 12, 24 and 48 months of follow-up.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Second cancer risk after treatment for HD is not low. Risk factors and preventive strategies are discussed.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kochbati</LastName><ForeName>L</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Service de radiothérapie carcinologie, institut Salah-Azaïz, boulevard Bab-Saadoun 1006 Tunis, Tunisie. lofti.kochbati@rns.tn</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Boussen</LastName><ForeName>H</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Benna</LastName><ForeName>F</ForeName><Initials>F</Initials></Author><Author ValidYN="Y"><LastName>Belhaj Ali</LastName><ForeName>Z</ForeName><Initials>Z</Initials></Author><Author ValidYN="Y"><LastName>Gammoudi</LastName><ForeName>A</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Bouaouina</LastName><ForeName>N</ForeName><Initials>N</Initials></Author><Author ValidYN="Y"><LastName>Besbes</LastName><ForeName>M</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Ghilen</LastName><ForeName>L</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Rahal</LastName><ForeName>K</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Maalej</LastName><ForeName>M</ForeName><Initials>M</Initials></Author></AuthorList><Language>FRE</Language><PublicationTypeList><PublicationType UI="D004740">English Abstract</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><VernacularTitle>Tumeurs secondaires après traitement pour maladie de Hodgkin en Tunisie. Etude rétrospective à propos de 26 cas observés à l'institut Salah-Azaïz.</VernacularTitle></Article><MedlineJournalInfo><Country>France</Country><MedlineTA>Cancer Radiother</MedlineTA><NlmUniqueID>9711272</NlmUniqueID><ISSNLinking>1278-3218</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>11056-06-7</RegistryNumber><NameOfSubstance UI="D001761">Bleomycin</NameOfSubstance></Chemical><Chemical><RegistryNumber>35S93Y190K</RegistryNumber><NameOfSubstance UI="D011344">Procarbazine</NameOfSubstance></Chemical><Chemical><RegistryNumber>50D9XSG0VR</RegistryNumber><NameOfSubstance UI="D008466">Mechlorethamine</NameOfSubstance></Chemical><Chemical><RegistryNumber>5J49Q6B70F</RegistryNumber><NameOfSubstance UI="D014750">Vincristine</NameOfSubstance></Chemical><Chemical><RegistryNumber>5V9KLZ54CY</RegistryNumber><NameOfSubstance UI="D014747">Vinblastine</NameOfSubstance></Chemical><Chemical><RegistryNumber>7GR28W0FJI</RegistryNumber><NameOfSubstance UI="D003606">Dacarbazine</NameOfSubstance></Chemical><Chemical><RegistryNumber>80168379AG</RegistryNumber><NameOfSubstance UI="D004317">Doxorubicin</NameOfSubstance></Chemical><Chemical><RegistryNumber>VB0R961HZT</RegistryNumber><NameOfSubstance UI="D011241">Prednisone</NameOfSubstance></Chemical></ChemicalList><SupplMeshList><SupplMeshName Type="Protocol" UI="C034632">ABVD protocol</SupplMeshName><SupplMeshName Type="Protocol" UI="C014553">MOPP protocol</SupplMeshName></SupplMeshList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000971" MajorTopicYN="N">Antineoplastic Combined Chemotherapy Protocols</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001761" MajorTopicYN="N">Bleomycin</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003606" MajorTopicYN="N">Dacarbazine</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004317" MajorTopicYN="N">Doxorubicin</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006689" MajorTopicYN="N">Hodgkin Disease</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000532" MajorTopicYN="Y">radiotherapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015994" MajorTopicYN="N">Incidence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008466" MajorTopicYN="N">Mechlorethamine</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016609" MajorTopicYN="N">Neoplasms, Second Primary</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011241" MajorTopicYN="N">Prednisone</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011344" MajorTopicYN="N">Procarbazine</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014416" MajorTopicYN="N" Type="Geographic">Tunisia</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014747" MajorTopicYN="N">Vinblastine</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014750" MajorTopicYN="N">Vincristine</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2003</Year><Month>10</Month><Day>3</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2003</Year><Month>11</Month><Day>13</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2003</Year><Month>10</Month><Day>3</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">14522350</ArticleId><ArticleId IdType="pii">S1278321803000817</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>Tunisie</li></country></list><tree><noCountry><name sortKey="Belhaj Ali, Z" sort="Belhaj Ali, Z" uniqKey="Belhaj Ali Z" first="Z" last="Belhaj Ali">Z. Belhaj Ali</name><name sortKey="Benna, F" sort="Benna, F" uniqKey="Benna F" first="F" last="Benna">F. Benna</name><name sortKey="Besbes, M" sort="Besbes, M" uniqKey="Besbes M" first="M" last="Besbes">M. Besbes</name><name sortKey="Bouaouina, N" sort="Bouaouina, N" uniqKey="Bouaouina N" first="N" last="Bouaouina">N. Bouaouina</name><name sortKey="Boussen, H" sort="Boussen, H" uniqKey="Boussen H" first="H" last="Boussen">H. Boussen</name><name sortKey="Gammoudi, A" sort="Gammoudi, A" uniqKey="Gammoudi A" first="A" last="Gammoudi">A. Gammoudi</name><name sortKey="Ghilen, L" sort="Ghilen, L" uniqKey="Ghilen L" first="L" last="Ghilen">L. Ghilen</name><name sortKey="Maalej, M" sort="Maalej, M" uniqKey="Maalej M" first="M" last="Maalej">M. Maalej</name><name sortKey="Rahal, K" sort="Rahal, K" uniqKey="Rahal K" first="K" last="Rahal">K. Rahal</name></noCountry><country name="Tunisie"><noRegion><name sortKey="Kochbati, L" sort="Kochbati, L" uniqKey="Kochbati L" first="L" last="Kochbati">L. Kochbati</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Terre/explor/CobaltMaghrebV1/Data/PubMed/Checkpoint
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000069 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd -nk 000069 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Terre
|area= CobaltMaghrebV1
|flux= PubMed
|étape= Checkpoint
|type= RBID
|clé= pubmed:14522350
|texte= [Second malignancies following Hodgkin's disease treatment in Tunisia. Retrospective study of 26 cases observed at the institute Salah-Azaïz].
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/RBID.i -Sk "pubmed:14522350" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd \
| NlmPubMed2Wicri -a CobaltMaghrebV1
| This area was generated with Dilib version V0.6.32. |  |